Genfit SA

(PINK:GNFTF)

Latest On Genfit SA (GNFTF):

Date/Time Type Description Signal Details
2023-05-12 04:55 ESTNewsGenfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball RollingN/A
2022-04-12 06:39 ESTNewsGenfit SA's (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call TranscriptN/A
2022-04-09 02:07 ESTNewsGenfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call TranscriptN/A
2021-03-18 07:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.32 to $11.29.Neutral
2021-03-17 18:42 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.34 to $11.32.Neutral
2021-03-14 06:48 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.37 to $11.34.Neutral
2021-03-13 05:53 ESTAnalyst RatingThe Analyst Target Price has increased from $11.32 to $11.37.Buy
2021-03-12 17:41 ESTAnalyst RatingThe Analyst Target Price has increased from $11.21 to $11.32.Buy
2021-03-12 06:15 ESTAnalyst RatingThe Analyst Target Price has increased from $11.18 to $11.21.Buy
2021-03-11 05:57 ESTAnalyst RatingThe Analyst Target Price has increased from $11.14 to $11.18.Buy
2021-03-10 06:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.21 to $11.14.Neutral
2021-03-09 06:04 ESTAnalyst RatingThe Analyst Target Price has increased from $11.19 to $11.21.Buy
2021-03-07 05:43 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.25 to $11.19.Neutral
2021-03-06 05:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.33 to $11.25.Neutral
2021-03-05 17:45 ESTAnalyst RatingThe Analyst Target Price has increased from $11.25 to $11.33.Buy
2021-03-05 09:57 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.29 to $11.25.Neutral
2021-03-04 17:46 ESTAnalyst RatingThe Analyst Target Price has increased from $9.34 to $11.29.Buy
2021-03-04 09:56 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.25 to $9.34.Neutral
2021-03-03 17:49 ESTAnalyst RatingThe Analyst Target Price has increased from $9.34 to $11.25.Buy
2021-03-03 10:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.29 to $9.34.Neutral
2021-03-02 10:01 ESTAnalyst RatingThe Analyst Target Price has increased from $11.27 to $11.29.Buy
2021-02-28 05:44 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.36 to $11.27.Neutral
2021-02-27 05:53 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.37 to $11.36.Neutral
2021-02-26 22:27 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.46 to $11.37.Neutral
2021-02-26 09:44 ESTAnalyst RatingThe Analyst Target Price has increased from $11.45 to $11.46.Buy
2021-02-25 06:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.46 to $11.45.Neutral
2021-02-24 06:33 ESTAnalyst RatingThe Analyst Target Price has increased from $11.42 to $11.46.Buy
2021-02-22 09:49 ESTAnalyst RatingThe Analyst Target Price has increased from $11.41 to $11.42.Buy
2021-02-21 05:48 ESTAnalyst RatingThe Analyst Target Price has increased from $11.39 to $11.41.Buy
2021-02-20 05:48 ESTAnalyst RatingThe Analyst Target Price has increased from $11.35 to $11.39.Buy
2021-02-19 17:26 ESTAnalyst RatingThe Analyst Target Price has increased from $11.29 to $11.35.Buy
2021-02-19 06:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.33 to $11.29.Neutral
2021-02-18 06:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.37 to $11.33.Neutral
2021-02-17 17:34 ESTAnalyst RatingThe Analyst Target Price has increased from $9.37 to $11.37.Buy
2021-02-17 05:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.36 to $9.37.Neutral
2021-02-15 05:56 ESTAnalyst RatingThe Analyst Target Price has increased from $11.35 to $11.36.Buy
2021-02-14 05:46 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.37 to $11.35.Neutral
2021-02-13 05:46 ESTAnalyst RatingThe Analyst Target Price has increased from $11.35 to $11.37.Buy
2021-02-12 05:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.09 to $11.35.Neutral
2021-02-11 17:36 ESTAnalyst RatingThe Analyst Target Price has increased from $14.02 to $14.09.Buy
2021-02-10 09:49 ESTAnalyst RatingThe Analyst Target Price has increased from $14 to $14.02.Buy
2021-02-07 05:46 ESTAnalyst RatingThe Analyst Target Price has increased from $13.92 to $14.Buy
2021-02-06 05:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $14 to $13.92.Neutral
2021-02-05 17:32 ESTAnalyst RatingThe Analyst Target Price has increased from $13.91 to $14.Buy
2021-02-05 06:12 ESTAnalyst RatingThe Analyst Target Price has increased from $11.56 to $13.91.Buy
2021-02-04 05:57 ESTAnalyst RatingThe Analyst Target Price has decreased from $13.95 to $11.56.Neutral
2021-02-03 05:48 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.01 to $13.95.Neutral
2021-02-02 06:41 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.03 to $14.01.Neutral
2021-01-31 05:52 ESTAnalyst RatingThe Analyst Target Price has increased from $14.01 to $14.03.Buy
2021-01-30 05:52 ESTAnalyst RatingThe Analyst Target Price has increased from $13.99 to $14.01.Buy

About Genfit SA (GNFTF):

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

See Advanced Chart

General

  • Name Genfit SA
  • Symbol GNFTF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 203
  • Last Split Factor1009:1000
  • Last Split Date2014-01-09
  • Fiscal Year EndDecember
  • Web URLhttp://www.genfit.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 5.57
  • Price/Book (Most Recent Quarter) 5.63
  • Enterprise Value Revenue 5.07
View More

Financials

  • Most Recent Quarter 2020-06-30
  • Profit Margin -172%
  • Return on Assets -14%
  • Return on Equity -105%
  • Revenue Per Share $0
  • Gross Profit 38.98 million
  • Quarterly Earnings Growth -0.1%
View More

Highlights

  • Market Capitalization 206.53 million
  • Analyst Target Price $11.29
  • Book Value Per Share $2.62
View More

Share Statistics

  • Shares Outstanding 41.84 million
  • Shares Float 37.14 million
  • % Held by Insiders 659%
  • % Held by Institutions 4.75%
View More

Technicals

  • Beta 1.18
  • 52 Week High $21.5
  • 52 Week Low $3.75
  • 50 Day Moving Average 5.18
  • 200 Day Moving Average 4.93
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Genfit SA (GNFTF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Genfit SA (GNFTF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-03-312020-06-30$N/A-$0.77-$0.67-14.4%
2019-12-312020-03-31$N/A-$0.75$0.00
2019-09-302019-12-31$N/A-$0.18$0.00
2019-06-302019-09-30$4.9 million-$0.18
2019-03-312019-06-30$4.75 million-$0.93-$0.65-43.46%
2018-12-312019-03-31$1.61 million-$0.92$0.00
2018-09-302018-12-31$1.64 million-$0.79$0.00
2018-06-302018-09-30$2.94 million-$0.80$0.00
2018-03-312018-06-30$3.1 million-$0.69$0.00
2017-12-312018-03-31$1.03 million-$0.72$0.00
2017-09-302017-12-31$1.03 million-$0.64$0.00
2017-06-302017-09-30$2.31 million-$0.63$0.00
2017-03-312017-06-30$2.31 million-$0.41$0.00
2016-12-312017-03-31$1.54 million-$0.39$0.00
2016-09-302016-12-31$1.54 million-$0.39$0.00
2016-06-302016-09-30-$0.42$0.00
2016-03-312016-06-30-$0.27$0.00
2015-12-312016-03-31-$0.28$0.00
2015-09-302015-12-31-$0.19$0.00
2015-06-302015-09-30-$0.19$0.00
2015-03-312015-06-30-$0.21$0.00
2014-12-312015-03-31-$0.20$0.00
2014-09-302014-12-31-$0.20$0.00
2014-06-302014-09-30-$0.21$0.00
2014-03-312014-06-30-$0.29$0.00
2013-12-312014-03-31-$0.30$0.00
2013-09-302013-12-31-$0.16$0.00
2013-06-302013-09-30-$0.16$0.00
2013-03-312013-06-30-$0.28$0.00
2012-12-312013-03-31-$0.28$0.00
2012-09-302012-12-31-$0.04$0.00
2012-06-302012-09-30-$0.04$0.00
2012-03-312012-06-30-$0.20$0.00
2011-12-312012-03-31-$0.21$0.00
2011-09-302011-12-31-$0.23$0.00
2011-06-302011-09-30-$0.24$0.00
2011-03-312011-06-30-$0.31$0.00
2010-12-312011-03-31-$0.30$0.00
2010-09-302010-12-31-$0.24$0.00

Genfit SA (GNFTF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Genfit SA (GNFTF) Chart:

Genfit SA (GNFTF) News:

Below you will find a list of latest news for Genfit SA (GNFTF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Genfit SA (GNFTF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Genfit SA (GNFTF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link